NOVARTIS SERVICES, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

1999–2017

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2017	—	4	1
2016	—	4	1
2015	—	14	3
2014	—	5	1
2011	—	2	1
2010	—	4	1
2009	—	6	1
2008	—	5	1
2001	—	2	1
2000	—	2	1
1999	—	2	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
PODESTA GROUP, INC.	—	38
RAMPY NORTHRUP LLC	—	5
OGR	—	5
BERGNER BOCKORNY CASTAGNETTI HAWKINS & BRAIN	—	2

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	44
HOUSE OF REPRESENTATIVES	43
Health & Human Services, Dept of (HHS)	17
Agriculture, Dept of (USDA)	4
Commerce, Dept of (DOC)	4
Environmental Protection Agency (EPA)	4
Executive Office of the President (EOP)	4
Centers For Medicare and Medicaid Services (CMS)	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	33
Budget/Appropriations	Budget/Appropriations	17
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	11
Defense	Defense	10
Medicare/Medicaid	Medicare/Medicaid	6
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	5
Pharmacy	Pharmacy	4
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	3

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2641115th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2017

2017 · fourth_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care policy and reform. Medical innovation. Cancer treatments. H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017. Issues related to drug pricing.

Client expense: — · Firm income: $30,000

Matched citations: H.R.2641

S. 540115th Congress

Mobile Workforce State Income Tax Simplification Act of 2017

2017 · fourth_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S.540 - Mobile Workforce State Income Tax Simplification Act of 2017

Client expense: — · Firm income: $30,000

Matched citations: S.540

H.R. 2641115th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2017

2017 · third_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care policy and reform. Medical innovation. Cancer treatments. H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017. Issues related to drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: H.R.2641

S. 540115th Congress

Mobile Workforce State Income Tax Simplification Act of 2017

2017 · third_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S.540 - Mobile Workforce State Income Tax Simplification Act of 2017

Client expense: — · Firm income: $50,000

Matched citations: S.540

Show 21 more cited filings

H.R. 2641115th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2017

2017 · second_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care policy and reform. Medical innovation. 21st Century Cures. Cancer treatments. H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017.

Client expense: — · Firm income: $50,000

Matched citations: H.R.2641

S. 540115th Congress

Mobile Workforce State Income Tax Simplification Act of 2017

2017 · second_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S.540 - Mobile Workforce State Income Tax Simplification Act of 2017

Client expense: — · Firm income: $50,000

Matched citations: S.540

H.R. 5182114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2016

2016 · fourth_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care policy. Medical innovation. 21st Century Cures. Cancer treatments. HR 5182/S. 2041, Promoting Life-Saving New Therapies for Neonates Act

Client expense: — · Firm income: $50,000

Matched citations: HR 5182

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2016 · fourth_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care policy. Medical innovation. 21st Century Cures. Cancer treatments. HR 5182/S. 2041, Promoting Life-Saving New Therapies for Neonates Act

Client expense: — · Firm income: $50,000

Matched citations: S. 2041

H.R. 5182114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2016

2016 · third_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care policy. Medical innovation. 21st Century Cures. Cancer treatments. HR 5182/S. 2041, Promoting Life-Saving New Therapies for Neonates Act

Client expense: — · Firm income: $50,000

Matched citations: HR 5182

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2016 · third_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care policy. Medical innovation. 21st Century Cures. Cancer treatments. HR 5182/S. 2041, Promoting Life-Saving New Therapies for Neonates Act

Client expense: — · Firm income: $50,000

Matched citations: S. 2041

H.R. 5182114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2016

2016 · second_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care and orphan drug policy. Medical innovation. 21st Century Cures. Cancer treatments. HR 5182/S. 2041, Promoting Life-Saving New Therapies for Neonates Act

Client expense: — · Firm income: $50,000

Matched citations: HR 5182

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2016 · second_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care and orphan drug policy. Medical innovation. 21st Century Cures. Cancer treatments. HR 5182/S. 2041, Promoting Life-Saving New Therapies for Neonates Act

Client expense: — · Firm income: $50,000

Matched citations: S. 2041

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2016 · first_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care and orphan drug policy. Medical innovation. 21st Century Cures. Cancer treatments. S. 2041, Promoting Life-Saving New Therapies for Neonates Act of 2015

Client expense: — · Firm income: $50,000

Matched citations: S. 2041

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2015 · fourth_quarter · Firm: PODESTA GROUP, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Health care and orphan drug policy. Medical innovation. 21st Century Cures. Cancer treatments. S. 2041, Promoting Life-Saving New Therapies for Neonates Act of 2015

Client expense: — · Firm income: $50,000

Matched citations: S. 2041

H.R. 3618114th Congress

Orphan Drug Fairness Act

2015 · fourth_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.6, 21st Century Cures Act. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015. H.R.3618, Orphan Drug Fairness Act. P.L.114-113, Consolidated Appropriations Act, 2016. Healthcare issues affecting pharmaceuticals, biologics, medical devices, and biosimilars.

Client expense: — · Firm income: $50,000

Matched citations: H.R.3618

H.R. 6114th Congress

21st Century Cures Act

2015 · fourth_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.6, 21st Century Cures Act. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015. H.R.3618, Orphan Drug Fairness Act. P.L.114-113, Consolidated Appropriations Act, 2016. Healthcare issues affecting pharmaceuticals, biologics, medical devices, and biosimilars.

Client expense: — · Firm income: $50,000

Matched citations: H.R.6

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2015 · fourth_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.6, 21st Century Cures Act. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015. H.R.3618, Orphan Drug Fairness Act. P.L.114-113, Consolidated Appropriations Act, 2016. Healthcare issues affecting pharmaceuticals, biologics, medical devices, and biosimilars.

Client expense: — · Firm income: $50,000

Matched citations: S.2041

H.R. 3618114th Congress

Orphan Drug Fairness Act

2015 · fourth_quarter · Firm: OGR

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3618, Orphan Drug Fairness Act; issues related to the orphan drug tax.

Client expense: — · Firm income: $30,000

Matched citations: H.R.3618

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2015 · fourth_quarter · Firm: OGR

Open original LDA filing ↗

Cited source text and reported amounts

General healthcare, pharmaceutical and Food and Drug Administration (FDA) related issues. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015; neonatal drug issues.

Client expense: — · Firm income: $30,000

Matched citations: S.2041

H.R. 3618114th Congress

Orphan Drug Fairness Act

2015 · third_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.6, 21st Century Cures Act. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015. H.R.3618, Orphan Drug Fairness Act. Healthcare issues affecting pharmaceuticals, biologics, medical devices, and biosimilars.

Client expense: — · Firm income: $50,000

Matched citations: H.R.3618

H.R. 6114th Congress

21st Century Cures Act

2015 · third_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.6, 21st Century Cures Act. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015. H.R.3618, Orphan Drug Fairness Act. Healthcare issues affecting pharmaceuticals, biologics, medical devices, and biosimilars.

Client expense: — · Firm income: $50,000

Matched citations: H.R.6

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2015 · third_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.6, 21st Century Cures Act. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015. H.R.3618, Orphan Drug Fairness Act. Healthcare issues affecting pharmaceuticals, biologics, medical devices, and biosimilars.

Client expense: — · Firm income: $50,000

Matched citations: S.2041

H.R. 3618114th Congress

Orphan Drug Fairness Act

2015 · third_quarter · Firm: OGR

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3618, Orphan Drug Fairness Act; issues related to the orphan drug tax.

Client expense: — · Firm income: $30,000

Matched citations: H.R.3618

S. 2041114th Congress

Promoting Life-Saving New Therapies for Neonates Act of 2015

2015 · third_quarter · Firm: OGR

Open original LDA filing ↗

Cited source text and reported amounts

General healthcare, pharmaceutical and Food and Drug Administration (FDA) related issues. S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015; neonatal drug issues.

Client expense: — · Firm income: $30,000

Matched citations: S.2041

H.R. 6114th Congress

21st Century Cures Act

2015 · second_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

P.L.114-10, Medicare Access and CHIP Reauthorization Act of 2015. H.R.6, 21st Century Cures Act. Healthcare issues affecting pharmaceuticals, biologics, medical devices, and biosimilars.

Client expense: — · Firm income: $50,000

Matched citations: H.R.6

Source: Senate LDA

NOVARTIS SERVICES, INC. — Lobbying Disclosure | Poliscope